You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,533,042


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,533,042
Title:Anti-notch NRR antibodies and methods using same
Abstract: The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies.
Inventor(s): Siebel; Christian W. (Berkeley, CA), Wu; Yan (Foster City, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:14/177,452
Patent Claims:1. A method for treating cancer in an individual, the method comprising administering an effective amount of a monoclonal anti-Notch1 negative regulatory region (NRR) antibody to the individual, wherein the antibody binds Notch1 NRR comprising amino acids 1447-1733 of SEQ ID NO:56, and wherein the cancer is not a T-cell leukemia.

2. The method of claim 1, wherein said cancer is a breast cancer.

3. The method of claim 1, wherein said cancer is a colon cancer.

4. The method of claim 1 further comprising administering to the individual an effective amount of a second medicament, wherein the anti-Notch1 NRR antibody is a first medicament.

5. The method of claim 4, wherein the second medicament is another antibody, a chemotherapeutic agent, a cytotoxic agent, an anti-angiogenic agent, an immunosuppressive agent, a prodrug, a cytokine, a cytokine antagonist, cytotoxic radiotherapy, a corticosteroid, an anti-emetic, a cancer vaccine, an analgesic, or a growth-inhibitory agent.

6. The method of claim 4, wherein the second medicament is tamoxifen, letrozole, exemestane, anastrozole, irinotecan, cetuximab, fulvestrant, vinorelbine, erlotinib, bevacizumab, vincristine, imatinib, sorafenib, lapatinib, or trastuzumab.

7. The method of claim 4, wherein the second medicament is administered prior to or subsequent to the administration of the anti-Notch1 NRR antibody.

8. The method of claim 4, wherein the second medicament is administered concurrently with the anti-Notch1 NRR antibody.

9. The method of claim 1, wherein Notch1 expression or a Notch1 ligand expression is determined in a biological sample of the individual before, during or after administration of the anti-Notch1 NRR antibody.

10. The method of claim 1, wherein said individual is a human.

11. The method of claim 1, wherein said anti-Notch1 NRR antibody binds human Notch1 NRR with a Kd of 1.times.10.sup.-7 or stronger.

12. The method of claim 11, wherein the Kd is determined by a surface plasmon resonance assay.

13. The method of claim 11, wherein the Kd is determined by a radiolabeled antigen binding assay.

14. The method of claim 1, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 9, 1, 2, 6.

15. The method of claim 1, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 10, 1, 3, 6.

16. The method of claim 1, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 11, 1, 4, 6.

17. The method of claim 1, wherein the antibody comprises HVR-L1, HVR-L2, HVR-L3, HVR-H1, HVR-H2, and HVR-H3, wherein each, in order, comprises SEQ ID NO:7, 8, 12, 1, 5, 6.

18. The method of claim 1, wherein the antibody induces cancer cell differentiation.

19. The method of claim 1, wherein the antibody reduces tumor angiogenesis.

20. The method of claim 1, wherein the cancer is associated with an activating mutation in Notch 1.

21. The method of claim 1, wherein the antibody comprises a heavy chain variable region sequence of SEQ ID NO:58, 60, 62 or 64, and a light chain variable region sequence of SEQ ID NO:59, 61, 63 or 65.

22. The method of claim 1, wherein the antibody decreases Notch 1 signaling.

23. The method of claim 22, wherein decreased Notch1 signaling is measured using a luciferase reporter assay.

24. The method of claim 23, wherein the antibody decreases Notch1 signaling by at least three fold below levels observed in the absence of the antibody.

25. The method of claim 22, wherein the antibody reduces signaling to about 18% of signaling in the absence of the antibody.

26. The method of claim 22, wherein the Notch1 signaling is ligand-mediated Notch1 signaling.

27. The method of claim 26, wherein the ligand is Jagged1.

28. The method of claim 1, wherein the antibody is a humanized or chimeric antibody.

Details for Patent 9,533,042

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2027-06-04
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2027-06-04
Eli Lilly And Company ERBITUX cetuximab Injection 125084 02/12/2004 ⤷  Try a Trial 2027-06-04
Eli Lilly And Company ERBITUX cetuximab Injection 125084 03/28/2007 ⤷  Try a Trial 2027-06-04
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Try a Trial 2027-06-04
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2027-06-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.